A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...
Treatment with the highest dose of investigational injectable amycretin -- a unimolecular GLP-1 and amylin receptor agonist -- yielded a 22% weight loss after 36 weeks in a phase Ib/IIa trial, said ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...
On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.
US stocks closed lower afer the S&P 500 touched an intraday record high early in the day. As tariff worries eased, mixed ...
As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...
Here are some of the major companies whose stocks moved on the week’s news.
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback